A growing body of evidence indicates that the anticancer effect of the immune system can be
activated by the immunogenic modulation of dying cancer cells. Cancer cell death, as a …

The tumor microenvironment (TME) is a dynamic and complex system that undergoes
continuous changes in its network architecture, notably affecting redox homeostasis. These …

Background Triple-negative breast cancer (TNBC) is an aggressive subtype of breast
cancer. Radiation therapy (RT) is a modality for TNBC management. Radiosensitizers can …

The highly pathogenic, novel coronavirus disease (COVID-19) outbreak has emerged as a
once-in-a-century pandemic with poor consequences, urgently calling for new therapeutics …

Chemotherapy resistance is still a serious problem in the treatment of most cancers. Many
cellular and molecular mechanisms contribute to both inherent and acquired drug …

Immunogenic cell death (ICD) can activate adaptive immune response in the host with
normal immune system. Some synthetic chemotherapeutic drugs and natural compounds …

Doxorubicin (DXR) is widely used in cancer treatment. However, it has not yet been possible
to prevent the side effects of DXR. The aim of this study was to investigate the …

Induction of immunogenic cell death (ICD) is a promising strategy for cancer
immunotherapy. Chrysin, which has potential anticancer effects, faces limitations in clinical …

Chrysin is a natural flavonoid with anti-cancer effects. Despite its beneficial effects, little
information is available regarding its immunogenic cell death (ICD) properties. In this work …

Background Immunogenic cell death (ICD) is a specific form of regulated cell death induced
by a variety of stressors. During ICD, the dying cancer cells release damage-associated …